VarmX and Rentschler Biopharma expand collaboration from early development to late ‑ stage and commercial manufacturing of VMX-C001 VMX ‑ C001 ...

Rentschler to manufacture VarmX’s VMX-C001 for Phase 3 development and potential commercialization.

Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities VarmX shareholders to receive initial $117m upfront and further potential milestone ...

Credit: Getty Images New research is being conducted on factor XI inhibitor therapy as the patent expiration for factor Xa inhibitors nears. Factor XI inhibitor therapy research is being conducted as ...

STOCKHOLM, Sweden – An experimental agent that prevents the formation of blood clots earlier in the coagulation process than other agents has cleared its first hurdle in becoming a potential new ...

Protease-activated receptors (PARs) constitute a unique family of G-protein-coupled receptors that are activated via proteolytic cleavage. Their role in cardiovascular disease extends beyond the ...